Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Prophylaxis of Acute Mountain Sickness
Interventions: Low Dose Acetazolamide, Normal Dose Acetazolamide; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lifestyle, Sedentary
Interventions: Exercise intervention; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma
Interventions: ALVAC-MART-1 vaccine, MART-1:26-35(27L) peptide vaccine, Aldesleukin, autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, incomplete Freund's adjuvant; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer, Ta/T1, CIS
Interventions: nadofaragene firadenovec; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Little Rock, Arkansas • Atlanta, Georgia

Conditions: High-Grade Early-Stage Bladder Cancer
Interventions: Low Intensity Surveillance, High Intensity Surveillance; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 2,482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: HIV Preexposure Prophylaxis
Interventions: ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions: amifostine trihydrate, cytarabine, mitoxantrone hydrochloride; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 4
States / cities: Chicago, Illinois • Kankakee, Illinois

Conditions: Acute Myeloid Leukemia (AML)
Interventions: cytarabine, daunorubicin hydrochloride, midostaurin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 1 more

Conditions: Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions: HspE7, placebo, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Orange, California

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: BSP Biological Signal Processing Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Cleveland, Ohio • Charlottesville, Virginia

Conditions: Aplastic Anemia, Paroxysmal Hemoglobinuria, Nocturnal
Interventions: cyclophosphamide, filgrastim; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 70 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy; Radiation · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes
Interventions: Collaborative Model of Primary care and Subspecialty care; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 18,268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Farmington, Connecticut • Arlington, Texas • Dallas, Texas

Conditions: Mood Disorders, Hypertension, Overweight and Obesity, Vascular Stiffness, Sleep, Elevated Blood Pressure
Interventions: Cardiovascular Assessments, Actigraphy, Laboratory assessments, Emotional/ Behavioural assessments; Diagnostic Test · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 22 Years
Enrollment: 37 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injuries, Paraplegia, Spinal, Tetraplegia/Tetraparesis, Paraplegia, Spastic
Interventions: Standing transspinal stimulation followed by robotic gait training, Lying transspinal stimulation followed by robotic gait training, Standing sham transspinal stimulation followed by robotic gait training; Combination Product · Other
Lead sponsor: City University of New York; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Staten Island, New York • The Bronx, New York

Conditions: Candidiasis, Candidemia
Interventions: voriconazole (Vfend); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoblastic Lymphoma, Acute Leukemia
Interventions: Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Orange, California

Conditions: Glioblastoma Multiforme, Glioma of Brain
Interventions: Ribociclib, Everolimus; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona

Conditions: Gestational Diabetes Mellitus
Interventions: Food is Medicine (FIM) Intervention, Standard of Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: filgrastim, carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 35 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions: bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate, vinorelbine tartrate, cyclophosphamide, etoposide phosphate, prednisone, filgrastim, ifosfamide; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 156
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 121 more

Conditions: Colorectal Cancer
Interventions: Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Digital Hypertension Management System, Usual Care; Other
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • Atlanta, Georgia • Eatonton, Georgia

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Rucaparib, Placebo; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more

Search by objective public record fields.

Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing

HIIT vs. MICT Training Study

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry

Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

Improving Chronic Disease Management With Pieces

Association of Mood With Risk for Atherosclerosis

Transspinal Stimulation Plus Locomotor Training for SCI

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Produce Rx in High Risk Pregnant Mothers at Harris Health

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

Technology-enabled Management Versus Usual Care for Blood Pressure

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)